Startup Funding News for the Day – Medtech Sector

CRESTWOOD, Ky.- Liberate Medical, an up-and-coming pioneer in the creation of cutting-edge, non-invasive neurostimulation devices aimed at revolutionizing respiratory treatment, announced the completion of its USD 6.2 million Series B fundraising round. Liberate Medical’s position as a top developer in respiratory and critical care will be strengthened by the funding, jointly sponsored by a significant strategic investor and Scientific Health Development, who will join the company’s board.

The only non-invasive, breath-synchronized neuromuscular electrical stimulator designed to stop expiratory muscle atrophy in mechanically ventilated patients is Liberate Medical’s VentFree Respiratory Muscle Stimulator. The funds will be used primarily to assist the PREVENT, a pivotal clinical trial for VentFree. The objective of the PREVENT trial is to show that VentFree shortens the time patients need invasive mechanical ventilation and may find it challenging to wean themselves. The dangers of extended automatic breathing, such as hospital-acquired infections, a decline in quality of life, and death, may be decreased by shortening the time patients are subject to it. The Series B funding will give the PREVENT trial the tools it needs to be finished in time for VentFree’s full commercial launch and FDA regulatory certification.

The PREVENT study is now underway after two productive pilot randomized controlled trials that were finished in Europe and Australia. VentFree possesses CE certification in the European Union, FDA Breakthrough Device Designation, and FDA Emergency Use Authorization.

Angus McLachlan, CEO of Liberate Medical, said, “We are happy to have Scientific Health Development and our strategic partner join us as co-leads in this Series B investment round. Their assistance and knowledge will be crucial as we carry out the PREVENT trial and become ready to fully commercialize VentFree.

According to Andrew Offer, the general partner and CEO of Scientific Health Development, Angus and the Liberate Medical team have the support of SHD. “It is an honor for me to join the board of directors and help alter the accepted practice for treating patients who are weaning from mechanical ventilation. Patients and their families quality of life will improve thanks to VentFree.

Liberate Medical manufactures medical equipment that creates technologies for neuromuscular electrical stimulation to enhance the standard of treatment and lower the cost for patients with pulmonary problems. 

We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! 

Next Article

Previous articleUSA-based Gooten raises USD 11 million in Series A
Next articleJapan-based laser company Ex-Fusion raises 1.8 billion yen in an oversubscribed seed funding round
Kshitij does business research and content writing for VCBay. Pursuing BBA from Symbiosis Center Of Management Studies (SCMS) Pune, he is skilled in Financial Modeling, Stock valuation and Microsoft Excel. He is passionate about Entrepreneurship and Finance.


Please enter your comment!
Please enter your name here